ZA200301465B - Vaccine composition comprising an antigen and a peptide having adjuvant properties. - Google Patents
Vaccine composition comprising an antigen and a peptide having adjuvant properties. Download PDFInfo
- Publication number
- ZA200301465B ZA200301465B ZA200301465A ZA200301465A ZA200301465B ZA 200301465 B ZA200301465 B ZA 200301465B ZA 200301465 A ZA200301465 A ZA 200301465A ZA 200301465 A ZA200301465 A ZA 200301465A ZA 200301465 B ZA200301465 B ZA 200301465B
- Authority
- ZA
- South Africa
- Prior art keywords
- peptide
- amino acid
- vaccine according
- acid residues
- antigen
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 199
- 239000000427 antigen Substances 0.000 title claims description 86
- 108091007433 antigens Proteins 0.000 title claims description 86
- 102000036639 antigens Human genes 0.000 title claims description 86
- 229960005486 vaccine Drugs 0.000 title claims description 52
- 239000002671 adjuvant Substances 0.000 title claims description 19
- 239000000203 mixture Substances 0.000 title description 21
- 125000000539 amino acid group Chemical group 0.000 claims description 53
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 30
- 230000028993 immune response Effects 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 19
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 13
- 230000004936 stimulating effect Effects 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 230000003308 immunostimulating effect Effects 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 229960003104 ornithine Drugs 0.000 claims description 5
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 3
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 claims description 3
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 3
- 229930010555 Inosine Natural products 0.000 claims description 3
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims description 3
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 3
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229960003786 inosine Drugs 0.000 claims description 3
- 150000007970 thio esters Chemical class 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 3
- 108010078791 Carrier Proteins Proteins 0.000 claims 3
- 150000001412 amines Chemical group 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 33
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 18
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 238000000034 method Methods 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000000890 antigenic effect Effects 0.000 description 12
- 108060001132 cathelicidin Proteins 0.000 description 12
- 102000014509 cathelicidin Human genes 0.000 description 12
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 11
- 150000001413 amino acids Chemical group 0.000 description 11
- 210000004443 dendritic cell Anatomy 0.000 description 11
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 11
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 10
- 230000000845 anti-microbial effect Effects 0.000 description 9
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 9
- 244000052769 pathogen Species 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000015788 innate immune response Effects 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 238000011510 Elispot assay Methods 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 108010051081 dopachrome isomerase Proteins 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- 230000004721 adaptive immunity Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 108010009352 antilipopolysaccharide factor (Limulus) Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 108010011110 polyarginine Proteins 0.000 description 3
- 229920002851 polycationic polymer Polymers 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 102000004082 Calreticulin Human genes 0.000 description 2
- 108090000549 Calreticulin Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 108010007004 cathelin Proteins 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- -1 iminothiocane Chemical compound 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 108010091748 peptide A Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940070376 protein Drugs 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 230000002483 superagonistic effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 201000005019 Chlamydia pneumonia Diseases 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 101000924587 Mus musculus Adenomatous polyposis coli protein Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 241001442539 Plasmodium sp. Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000004395 cytoplasmic granule Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000030773 pneumonia caused by chlamydia Diseases 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0178900A AT410635B (de) | 2000-10-18 | 2000-10-18 | Vakzin-zusammensetzung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200301465B true ZA200301465B (en) | 2004-02-24 |
Family
ID=3688953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200301465A ZA200301465B (en) | 2000-10-18 | 2003-02-24 | Vaccine composition comprising an antigen and a peptide having adjuvant properties. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8361476B2 (hu) |
| EP (1) | EP1326634B1 (hu) |
| JP (2) | JP4227407B2 (hu) |
| KR (1) | KR100598302B1 (hu) |
| CN (1) | CN1248736C (hu) |
| AT (2) | AT410635B (hu) |
| AU (2) | AU2002212326B2 (hu) |
| BR (1) | BRPI0114994B8 (hu) |
| CA (1) | CA2426490C (hu) |
| CZ (1) | CZ303303B6 (hu) |
| DE (1) | DE60119145T2 (hu) |
| DK (1) | DK1326634T3 (hu) |
| ES (1) | ES2263668T3 (hu) |
| HK (1) | HK1055899A1 (hu) |
| HU (1) | HU228382B1 (hu) |
| IL (2) | IL154605A0 (hu) |
| IS (1) | IS2608B (hu) |
| MX (1) | MXPA03002828A (hu) |
| NO (1) | NO330274B1 (hu) |
| NZ (1) | NZ524532A (hu) |
| PL (1) | PL209016B1 (hu) |
| PT (1) | PT1326634E (hu) |
| RU (2) | RU2328305C2 (hu) |
| SI (1) | SI1326634T1 (hu) |
| SK (1) | SK287618B6 (hu) |
| WO (1) | WO2002032451A1 (hu) |
| ZA (1) | ZA200301465B (hu) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT410635B (de) * | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| US7244438B2 (en) | 2001-01-05 | 2007-07-17 | Intercell Ag | Uses for polycationic compounds |
| EP1347775B1 (en) * | 2001-01-05 | 2016-11-30 | Valneva Austria GmbH | Uses for polycationic compounds as vaccine adjuvants |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| EP1279404A1 (en) | 2001-07-26 | 2003-01-29 | Istituto Superiore di Sanità | Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| US7528223B2 (en) | 2002-07-24 | 2009-05-05 | Intercell Ag | Antigens encoded by alternative reading frames from pathogenic viruses |
| US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| WO2004024182A2 (en) | 2002-09-13 | 2004-03-25 | Intercell Ag | Method for isolating hepatitis c virus peptides |
| EP2314604A3 (en) | 2002-10-15 | 2011-05-25 | Intercell AG | Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof |
| CN102512670A (zh) | 2003-03-04 | 2012-06-27 | 英特塞尔股份公司 | 化脓链球菌抗原 |
| CN100355453C (zh) * | 2003-03-24 | 2007-12-19 | 英特塞尔股份公司 | 改进的疫苗 |
| AU2004224746B2 (en) | 2003-03-24 | 2009-04-23 | Valneva Austria Gmbh | Improved vaccines |
| WO2004087746A2 (en) | 2003-03-31 | 2004-10-14 | Intercell Ag | Staphylococcus epidermidis antigens |
| EP2298934A1 (en) | 2003-04-15 | 2011-03-23 | Intercell AG | S. pneumoniae antigens |
| US8076059B2 (en) | 2003-04-16 | 2011-12-13 | Duke University | Adjuvant capable of specifically activating the adaptive immune response |
| CA2522986A1 (en) | 2003-05-07 | 2004-11-18 | Intercell Ag | Streptococcus agalactiae antigens i + ii |
| EP2267006A1 (en) | 2003-05-30 | 2010-12-29 | Intercell AG | Enterococcus antigens |
| DE602004030343D1 (de) * | 2003-07-11 | 2011-01-13 | Intercell Ag | Hcv-vakzin |
| ES2297688T3 (es) | 2004-03-12 | 2008-05-01 | Intercell Ag | Procedimiento para solubizar mezclas de peptidos. |
| PL1791858T3 (pl) | 2004-09-24 | 2010-09-30 | Intercell Ag | Zmodyfikowane białko kapsydowe VP1 z parwowirusa B19 |
| WO2007044382A2 (en) | 2005-10-07 | 2007-04-19 | Health Protection Agency | Proteins with improved solubility and methods for producing and using same |
| TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| DK2040745T3 (da) | 2006-06-28 | 2013-03-18 | Statens Seruminstitut | Udvidelse af T-celle repertoiret til at omfatter subdominante epitoper ved vacci-nation med antigener leveret som proteinfragmenter eller peptidblandinger |
| JP2009542196A (ja) | 2006-07-07 | 2009-12-03 | インターセル アーゲー | 小型の化膿連鎖球菌抗原およびそれらの使用 |
| CA2661224A1 (en) | 2006-09-15 | 2008-03-20 | Intercell Ag | Borrelia antigens |
| EP1923069A1 (en) | 2006-11-20 | 2008-05-21 | Intercell AG | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| EP2120984A2 (en) | 2007-01-12 | 2009-11-25 | Intercell AG | Protective proteins of s. agalactiae, combinations thereof and methods of using the same |
| EP2152731A2 (en) | 2007-05-02 | 2010-02-17 | Intercell AG | Klebsiella antigens |
| ES2602610T3 (es) | 2007-05-31 | 2017-02-21 | Medigene Ag | Proteína estructural mutada de un parvovirus |
| EP2012122A1 (en) | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| WO2008155291A2 (en) | 2007-06-18 | 2008-12-24 | Intercell Ag | Chlamydia antigens |
| WO2009115508A2 (en) | 2008-03-17 | 2009-09-24 | Intercell Ag | Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto |
| KR101614344B1 (ko) | 2008-04-02 | 2016-04-21 | 토쿠시마 대학 | 합성 펩티드를 함유하는 항원약물 비이클과 이것을 사용하는 점막 백신 |
| MX2010014358A (es) | 2008-06-20 | 2011-07-04 | Wyeth Llc | Composiciones y metodos de uso del orf1358 de cepas estreptococicas beta-hemoliticas. |
| US20100015171A1 (en) * | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
| WO2010089340A2 (en) | 2009-02-05 | 2010-08-12 | Intercell Ag | Peptides protective against e. faecalis, methods and uses relating thereto |
| EP2405938A2 (en) | 2009-02-13 | 2012-01-18 | Intercell AG | Nontypable haemophilus influenzae antigens |
| MX2012000044A (es) | 2009-06-22 | 2012-01-30 | Wyeth Llc | Composiciones inmunogenicas de antigenos de staphylococcus aureus. |
| AU2010301043B2 (en) | 2009-06-22 | 2014-01-09 | Wyeth Llc | Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| AU2010288239B2 (en) | 2009-08-27 | 2014-01-16 | Novartis Ag | Adjuvant comprising aluminium, oligonucleotide and polycation |
| EP2308896A1 (en) | 2009-10-09 | 2011-04-13 | Sanofi-aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| EP2319871A1 (en) | 2009-11-05 | 2011-05-11 | Sanofi-aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| MX2012004090A (es) | 2009-10-09 | 2012-04-20 | Sanofi Sa | Polipeptidos para unirse al "receptor para productos terminales de glicacion avanzados" asi como composiciones y metodos que involucran los mismos. |
| US8765148B2 (en) | 2010-02-19 | 2014-07-01 | Valneva Austria Gmbh | 1C31 nanoparticles |
| EP2547357A1 (en) | 2010-03-18 | 2013-01-23 | Novartis AG | Adjuvanted vaccines for serogroup b meningococcus |
| CN102933229A (zh) | 2010-06-04 | 2013-02-13 | 惠氏有限责任公司 | 疫苗制剂 |
| WO2012025873A2 (en) | 2010-08-23 | 2012-03-01 | Wyeth Llc | STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS |
| DK2753352T4 (da) | 2010-09-03 | 2022-09-12 | Valneva Austria Gmbh | Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf |
| AR082925A1 (es) | 2010-09-08 | 2013-01-16 | Medigene Ag | Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados |
| PE20140173A1 (es) | 2010-09-10 | 2014-02-20 | Wyeth Llc | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis |
| BR112013016153A2 (pt) | 2010-12-22 | 2017-07-11 | Wyeth Llc | composições imunogênicas estáveis de antígenos de staphylococcus aureus |
| BRPI1100857A2 (pt) * | 2011-03-18 | 2013-05-21 | Alexandre Eduardo Nowill | agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real |
| ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
| SG10201602558UA (en) | 2012-03-09 | 2016-05-30 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| AU2013259598B2 (en) * | 2012-05-08 | 2018-10-04 | Western University Of Health Sciences | Standardized ex vivo platforms for the antigen-specific expansion of CD4+ T cell populations |
| CN104884069B (zh) * | 2012-10-29 | 2018-11-27 | 阿肯色大学评议会 | 新的黏膜佐剂和递送系统 |
| EP3363806B1 (en) | 2012-12-20 | 2022-11-16 | Pfizer Inc. | Glycoconjugation process |
| EP2964665B1 (en) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
| US20140271723A1 (en) * | 2013-03-15 | 2014-09-18 | Saint Louis University | Adjuvant compositions and methods of using thereof |
| CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| WO2016130569A1 (en) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
| BR112017017460A2 (pt) | 2015-02-19 | 2018-04-10 | Pfizer Inc. | composições de neisseria meningitidis e métodos das mesmas |
| MY182282A (en) | 2015-05-04 | 2021-01-18 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| CN107441501B (zh) * | 2016-07-01 | 2020-11-10 | 四川大学 | 抗菌肽修饰的载药脂质体及其制备方法和用途 |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| CN107266585B (zh) * | 2017-07-13 | 2019-08-06 | 陕西科技大学 | 一种mlh融合抗菌肽及其制备方法和应用 |
| AU2019220386A1 (en) | 2018-02-16 | 2020-08-20 | 2A Pharma Ab | Parvovirus structural protein for the treatment of autoimmune diseases |
| EP3527223A1 (en) | 2018-02-16 | 2019-08-21 | 2A Pharma AB | Mutated parvovirus structural protein |
| CN109745556A (zh) * | 2019-03-01 | 2019-05-14 | 龙阔（苏州）生物工程有限公司 | 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗 |
| KR20220010478A (ko) | 2019-05-20 | 2022-01-25 | 발네바 에스이 | 기도 감염의 치료 또는 예방용 서브유닛 백신 |
| US20230137756A1 (en) * | 2020-03-30 | 2023-05-04 | The Wistar Institute Of Anatomy And Biology | Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19 |
| WO2021211279A1 (en) | 2020-04-17 | 2021-10-21 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
| US20230321212A1 (en) | 2020-08-26 | 2023-10-12 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| AU2022255923A1 (en) | 2021-04-09 | 2023-08-31 | Valneva Se | Human metapneumo virus vaccine |
| WO2023083964A1 (en) | 2021-11-11 | 2023-05-19 | 2A Pharma Ab | Parvovirus structural protein against beta- and gamma-hpv |
| WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ271774A (en) * | 1993-08-06 | 1998-02-26 | Cytel Corp | Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen |
| JP3442824B2 (ja) * | 1993-08-30 | 2003-09-02 | 理化学研究所 | 抗菌性ペプチド類 |
| JP3547504B2 (ja) * | 1994-11-01 | 2004-07-28 | 独立行政法人理化学研究所 | 新規なポリペプチド及びその用途 |
| US6261568B1 (en) * | 1997-06-11 | 2001-07-17 | Institut Pasteur | Attenuated recombinant mycobacteria useful as immunogens or as vaccine components |
| AU760034B2 (en) * | 1997-08-29 | 2003-05-08 | Corixa Corporation | Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof |
| CU22700A1 (es) * | 1997-09-29 | 2001-07-31 | Ct Ingenieria Genetica Biotech | Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso |
| US20020072495A1 (en) * | 2000-09-21 | 2002-06-13 | Oleg Chertov | LL-37 is an immunostimulant |
| AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| CN100355453C (zh) * | 2003-03-24 | 2007-12-19 | 英特塞尔股份公司 | 改进的疫苗 |
| AU2004224746B2 (en) | 2003-03-24 | 2009-04-23 | Valneva Austria Gmbh | Improved vaccines |
| DE602004030343D1 (de) * | 2003-07-11 | 2011-01-13 | Intercell Ag | Hcv-vakzin |
-
2000
- 2000-10-18 AT AT0178900A patent/AT410635B/de not_active IP Right Cessation
-
2001
- 2001-10-18 WO PCT/EP2001/012041 patent/WO2002032451A1/en active IP Right Grant
- 2001-10-18 SK SK575-2003A patent/SK287618B6/sk not_active IP Right Cessation
- 2001-10-18 SI SI200130564T patent/SI1326634T1/sl unknown
- 2001-10-18 CN CNB018171168A patent/CN1248736C/zh not_active Expired - Lifetime
- 2001-10-18 KR KR1020037004977A patent/KR100598302B1/ko active IP Right Grant
- 2001-10-18 IL IL15460501A patent/IL154605A0/xx unknown
- 2001-10-18 DK DK01980496T patent/DK1326634T3/da active
- 2001-10-18 DE DE60119145T patent/DE60119145T2/de not_active Expired - Lifetime
- 2001-10-18 HU HU0302117A patent/HU228382B1/hu unknown
- 2001-10-18 CZ CZ20031299A patent/CZ303303B6/cs not_active IP Right Cessation
- 2001-10-18 NZ NZ524532A patent/NZ524532A/en not_active IP Right Cessation
- 2001-10-18 CA CA2426490A patent/CA2426490C/en not_active Expired - Lifetime
- 2001-10-18 AU AU2002212326A patent/AU2002212326B2/en not_active Expired
- 2001-10-18 ES ES01980496T patent/ES2263668T3/es not_active Expired - Lifetime
- 2001-10-18 EP EP01980496A patent/EP1326634B1/en not_active Expired - Lifetime
- 2001-10-18 AU AU1232602A patent/AU1232602A/xx active Pending
- 2001-10-18 RU RU2003114434/15A patent/RU2328305C2/ru active
- 2001-10-18 US US10/399,442 patent/US8361476B2/en active Active
- 2001-10-18 AT AT01980496T patent/ATE324116T1/de not_active IP Right Cessation
- 2001-10-18 JP JP2002535688A patent/JP4227407B2/ja not_active Expired - Lifetime
- 2001-10-18 MX MXPA03002828A patent/MXPA03002828A/es active IP Right Grant
- 2001-10-18 BR BR0114994-6 patent/BRPI0114994B8/pt not_active IP Right Cessation
- 2001-10-18 PT PT01980496T patent/PT1326634E/pt unknown
- 2001-10-18 PL PL362966A patent/PL209016B1/pl unknown
-
2003
- 2003-02-20 IS IS6722A patent/IS2608B/is unknown
- 2003-02-24 ZA ZA200301465A patent/ZA200301465B/en unknown
- 2003-02-24 IL IL154605A patent/IL154605A/en unknown
- 2003-04-08 NO NO20031595A patent/NO330274B1/no not_active IP Right Cessation
- 2003-11-12 HK HK03108189A patent/HK1055899A1/xx not_active IP Right Cessation
-
2007
- 2007-12-13 RU RU2007146372/15A patent/RU2007146372A/ru not_active Application Discontinuation
-
2008
- 2008-05-21 US US12/124,785 patent/US8900564B2/en active Active
- 2008-05-22 JP JP2008134215A patent/JP2008222721A/ja not_active Withdrawn
-
2013
- 2013-01-16 US US13/742,500 patent/US20130216583A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2426490C (en) | Vaccine composition comprising an antigen and a peptide having adjuvant properties | |
| AU2002212326A1 (en) | Vaccine composition comprising an antigen and a peptide having adjuvant properties | |
| JP2008222721A6 (ja) | ワクチン組成物 | |
| AU784403B2 (en) | Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants | |
| Xu et al. | Bioconjugation approaches to producing subunit vaccines composed of protein or peptide antigens and covalently attached toll-like receptor ligands | |
| AU2001289813A1 (en) | A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof | |
| WO2002013857A2 (en) | A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof | |
| US20070041998A1 (en) | Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses | |
| JP2004519452A (ja) | ポリカチオン性化合物の用途 | |
| AU2002340561B2 (en) | Use of peptide vectors to improve the immune response to antigens |